Designing phase II B trials in sarcopenia: The best target population

Journal of Nutrition, Health and Aging

Volumn 15, Issue 8, 2011, Pages 725-730

  Pahor, M ^a   Cesari, Matteo ^b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

aging; clinical trials; muscle strength; older persons; Sarcopenia; skeletal muscle; study design

Indexed keywords

AGING; ARTICLE; HUMAN; MEDICAL RESEARCH; MUSCLE ATROPHY; MUSCLE FUNCTION; MUSCLE MASS; MUSCLE STRENGTH; MUSCLE WEAKNESS; PHASE 2 CLINICAL TRIAL (TOPIC); POPULATION RESEARCH; PRIORITY JOURNAL; STUDY DESIGN;

EID: 84856280227     PISSN: 12797707     EISSN: 17604788     Source Type: Journal    
DOI: 10.1007/s12603-011-0058-9     Document Type: Article

References (54)

1. Rosenberg IH. Sarcopenia origins and clinical relevance. JNutr. 1997;127(5 Suppl):990S.
2. Abellan van Kan G, Andre E, Bischoff Ferrari HA, Boirie Y, Onder G, Pahor M et al. Carla Task Force on Sarcopenia propositions for clinical trials. J Nutr Health Aging. 2009;13(8):700.
3. Cesari M, Ferrini A Zamboni V, Pahor M. Sarcopenia current clinical and research issues. Open Geriatr Med J. 2008; 1:14.
4. Janssen I, Baumgartner RN, Ross R, Rosenberg IH, Roubenoff R. Skeletal muscle cutpoints associated with elevated physical disability risk in older men and women. Am J Epidemiol. 2004;159(4):413. (Pubitemid 38200776)
5. Visser M, Kritchevsky SB, Goodpaster BH, Newman AB, Nevitt M, Stamm E et al. Leg muscle mass and composition in relation to lower extremity performance in men and women aged 70 to 79: the health aging and body composition study. J Am Geriatr Soc. 2002;50(5):897. (Pubitemid 34496688)
6. Janssen I, Heymsfield SB, Ross R. Low relative skeletal muscle mass (sarcopenia) in older persons is associated with functional impairment and physical disability. J Am Geriatr Soc. 2002;50(5):889. (Pubitemid 34496687)
7. Cesari M, Pahor M, Lauretani F, Zamboni V, Bandinelli S, Bernabei R et al. Skeletal Muscle and Mortality Results From the InCHLANTi Study. J Gerontol A Biol Sci Med Sci. 2009
8. Goodpaster BH, Park SW, Harris TB, Kritchevsky SB, Nevitt M, Schwartz AV et al. The loss of skeletal muscle strength, mass, and quality in older adults: the health, aging and body composition study. J Gerontol A Biol Sci Med Sci. 2006;61(10):1059.
9. Newman AB, Kupelian V, Visser M, Simonsick EM, Goodpaster BH, Kritchevsky SB et al. Strength, but not muscle mass, is associated with mortality in the health, aging and body composition study cohort. J Gerontol A Biol Sci Med Sci. 2006;61(1):72.
10. Cesari M, Pahor M. Target population for clinical trials on sarcopenia. J Nutr Health Aging. 2008;12(7):470.
11. Studenski S. Target population for clinical trials. J Nutr Health Aging. 2009;13(8):729.
12. Cruz-Jentoft AT, Baeyeas JP, Bauer JM, Boirie Y, Cederholm T, Landi F et al. Sarcopenia European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age and Ageing. 2010;39(4):412.
13. Clark BC, Manini TM. Sarcopenia =/= dynapenia. J Gerontol A Biol Sci Med Sci. 2008;63(8):829.
14. Morley JE, Baumgartner RN, Roubenoff R, Mayer J, Nair KS. Sarcopenia. J Lab Clin Med. 2001;137(4):231. (Pubitemid 32296061)
15. Stenholm S, Harris TB, Rantanen T, Visser M, Kritchevsky SB, Ferrucci L. Sarcopenic obesity: definition, cause and consequences. Curr Opin Clin Nutr Metab Care. 2008;11(6):693.
16. Zamboni M, Mazzali G, Fantin F, Rossi A, Di Francesco V. Sarcopenic obesity: a new category of obesity in the elderfy. Nutr Metab Cardiovasc Dis. 2008; 18(5):388.
17. Cesari M, Kritchevsky SB, Baumgartner RN, Atkinson HH, Penniax BW, Lenchik L et al. Sarcopenia, obesity, and inflammation-results from the Trial of Angiotensin Converting Enzyme Inhibition and Novel Cardiovascular Risk Factors study. Am J Clin Nutr. 2005;82(2):428.
18. Newman AB, Kupelian V, Visser M, Simoasick E, Goodpaster B, Nevitt M et al. Sarcopenia alternative definitions and associations with lower extremity function. J Am Geriatr Soc. 2003;51(11): 1602. (Pubitemid 37409595)
19. Leeuwenburgh C. Role of apoptosis in sarcopenia. J Gerontol A Biol Sci Med Sci. 2003;58(11):999.
20. Dirks AJ, Hofer T, Marzetti E, Pahor M, Leeuwenburgh C. Mitochondrial DNA mutations, energy metabolism and apoptosis in aging muscle. Ageing Res Rev. 2006;5(2):179. (Pubitemid 43786295)
21. Roubenoff R. Physical activity, inflammation, and muscle loss. Nutr Rev. 2007;65(12 Pt 2):S208.
22. Srikanthan P, Hevener AL, Karlamangla AS. Sarcopenia exacerbates obesity-associated insulin-resistance and dysglycemia findings from the National Health and Nutrition Examination Survey HI. PLoS One. 2010;5(5)el0805.
23. Thall PF, Simon R. Practical Bayesian guidelines for phase ECB clinical trials. Biometrics. 1994;50(2):337. (Pubitemid 24230614)
24. Gray R, Manola J, Saxman S, Wright J, Dutcher J, Atkins M et al Phase II clinical trial design: methods in translational research from the Genitourinary Committee at the Eastern Cooperative Oncology Group. Clin Cancer Res. 2006;12(7 Pt 1):1966.
25. Case LD, Morgan TM. Design of Phase II cancer trials evaluating survival probabilities. BMC Med Res Methodol. 2003;3:6.
26. Fleming TR, DeMets DL. Surrogate end points in clinical trials: are we being misled? Ann Intern Med. 1996;125(7):605.
27. Beenakker KG, Ling CH, Meskers CG, de Craen AJ, Stijnen T, Westendorp RG et al. Patterns of muscle strength loss with age in the general population and patients with a chronic inflammatory state. Ageing Res Rev. 2010
28. Walsmith J, Roubenoff R. Cachexia in rheumatoid arthritis. Int J Cardiol. 2002;85(1):89.
29. Giles JT, Ling SM, Ferrucci L, Bartlett SJ, Andersen RE, Towns M et al. Abnormal body composition phenotypes in older rheumatoid arthritis patients: association with disease characteristics and pharmacotherapies. Arthritis Rheum. 2008;59(6):807. (Pubitemid 351847563)
30. Roubenoff R. Sarcopenic obesity: does muscle loss cause fat gain? Lessons from rheumatoid arthritis and osteoarthritis. Ann NY Acad Sci. 2000:904:553.
31. Cesari M, Kritchevsky SB, Penniax BW, Nicklas BJ, Simonsick EM, Newman AB et al. Prognostic value of usual gait speed in well-functioning older people-results from the Health, Aging and Body Composition Study. J Am Geriatr Soc. 2005;53(10): 1675. (Pubitemid 43109929)
32. Manini TM, Visser M, Won-Park S, Patel KV, Strotmeyer ES, Chen H et al. Knee extension strength cutpoints for maintaining mobility. J Am Geriatr Soc. 2007;55(3):451. (Pubitemid 46328122)
33. Guralnik JM, Ferrucci L, Pieper CF, Leveille SG, Markides KS, Ostir GV et al. Lower extremity function and subsequent disability: consistency across studies, predictive models, and value of gait speed alone compared with the short physical performance battery. J Gerontol ABiol SciMed Sci. 2000;55(4):M221.
34. Guralnik JM, Ferrucci L, Simonsick EM, Salive ME, Wallace RB. Lower-extremity function in persons over the age of 70 years as a predictor of subsequent disability. N Engl J Med. 1995;332(9):556.
35. Manini TM, Visser M, Won-Park S, Patel KV, Strotmeyer ES, Chen H, Goodpaster B, De Rekeneire N, Newman AB, Simonsick EM, Kritchevsky SB, Ryder K, Schwartz AV, Harris TB. Knee extension strength cutpoints for maintaining mobility. J Am Geriatr Soc 2007;55(3):451. (Pubitemid 46328122)
36. Bortz WMn. A conceptual framework of frailty: a review. J Gerontol A Biol Sci Med Sci. 2002;57(5):M283.
37. Baumgartner RN, Koehler KM, Gallagher D, Romero L, Heymsfield SB, Ross RR et al. Epidemiology of sarcopenia among the elderly in New Mexico. Am J Epidemiol. 1998;147(8):755.
38. Melton L Jr, Khosla S, Crowson CS, O'Connor MK, O'Fallon WM, Riggs BL. Epidemiology of sarcopenia, J Am Geriatr Soc. 2000;48(6):625.
39. Castaneda C, Janssen I. Ethnic comparisons of sarcopenia and obesity in diabetes. Ethn Dis.2005;15(4):664.
40. Wang Z, Heo M, Lee RC, Kotier DP, Withers RT, Heymsfield SB. Muscularity in adult humans: proportion of adipose tissue-free body mass as skeletal muscle. Am J Hum Biol 2001;13(5):612. (Pubitemid 32771404)
41. Gallagher D, Heymsfield SB, Heo M, Jebb SA, Murgatroyd PR, Sakamoto Y. Healthy percentage body fat ranges: an approach for developing guidelines based on body mass index. Am J Clin Nutr. 2000;72(3):694.
42. Goodpaster BH, Carlson CL, Visser M, Kelley DE, Scherzinger A, Harris TB et al. Attenuation of skeletal muscle and strength in the elderly: The Health ABC Study. J AppI Physiol 2001;90(6):2157.
43. Garcia-Martinez C, Lopez-Soriano FJ, Argiles JM. Acute treatment with tumour necrosis factor-alpha induces changes in protein metabolism in rat skeletal muscle. Mol Cell Biochem. 1993;125(1): 11.
44. Charters Y, Grimble RF. Effect of recombinant human tumour necrosis factor alpha on protein synthesis in liver, skeletal muscle and skin of rats. Biochem J. 1989;258(2):493.
45. Schaap LA, Pluijm SM, Deeg DJ, Harris TB, Kritchevsky SB, Newman AB et al. Higher inflammatory marker levels in older persons: associations with 5-year change in muscle mass and muscle strength. J Gerontol A Biol Sci Med Sci. 2009;64(11): 1183.
46. Roubenoff R. Catabolism of aging: is it an inflammatory process? Curr Opin Clin Nutr Metab Care. 2003;6(3):295.
47. Eisenstaedt R, Penniax BW, Woodman RC. Anemia in the elderly: current understanding and emerging concepts. Blood Rev. 2006;20(4):213. (Pubitemid 43729336)
48. Tipton KD, Ferrando AA. Improving muscle mass: response of muscle metabolism to exercise, nutrition and anabolic agents. Essays Biochem. 2008;44:85.
49. Herbst KL, Bhasia S. Testosterone action on skeletal muscle. Curr Opin Clian Nutr Metab Care. 2004;7(3):271. (Pubitemid 40340664)
50. Perrini S, Laviola L, Carreira MC, Cignarelli A, Natalicchio A, Giorgiao F. The GHIGF1 axis and signaling pathways in the muscle and bone: mechanisms underlying age-related skeletal muscle wasting and osteoporosis. J Endocrinol. 2010;205(3):201.
51. Cesari M, Kritchevsky SB, Leeuwenburgh C, Pahor M. Oxidative damage and platelet activation as new predictors of mobility disability and mortality in elders. Antioxid Redox Signal 2006;8(3-4):609. (Pubitemid 43741329)
52. Azuma K, Heilbrona LK, Albu JB, Smith SR, Ravussin E, Kelley DE. Adipose tissue distribution in relation to insulin resistance in type 2 diabetes mellitus. Am J Physiol Endocrinol Metab. 2007;293(1):E435. (Pubitemid 47105959)
53. Pradhan AD, Maason JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin6, and risk of developing type 2 diabetes mellitus. JAMA 2001;286(3):327.
54. Anker SD, Sharma R. Thesyndrome of cardiac cachexia. Int J Cardiol. 2002;85(1):51.